ADMA Biologics (ADMA) closed at $10.18 on Oct 6, 2026, up 0.7% on the day. The stock is up 5.8% over the past month, up 11.1% over three months, down 44.2% year to date and down 30.6% over the past year. It trades 50.2% below its 52-week high of $20.46 and 41.2% above its 52-week low of $7.21. The close sits above its 50-day moving average ($9.48) and below its 200-day moving average ($11.66).
Over its last 8 reports the stock moved an average of 9.8% on the first trading day after earnings, beating the options-implied move in 1 of 8.
Over the last 8 reports, ADMA moved an average of 9.8% on the first trading day after earnings. The move beat the options-implied move in 1 of 8 reports.
No — the Oct 6, 2026 close of $10.18 is 12.7% below the 200-day average of $11.66.
ADMA closed 50.2% below its 52-week high of $20.46.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
